Replies to post #612 on Second Sight Medical Products Inc (EYES)

[zitry]

I believe Q4 sales will be lackluster. Q1 should be the break through quarter for sales with Medicare and major insurance companies all kicking in with reimbursement in 2019. Anybody's guess how the market will receive what I think will be ho hum sales similar to Q3. Indications have been ORION results are very good. If so, this could be a catalyst. Hope next generation ARGUS is ready to go. I wonder if EYES will have the foresight to report backlog?